The non-toxic and biodegradable adjuvant Montanide ISA 720/CpG can replace Freund's in a cancer vaccine targeting ED-B-a prerequisite for clinical development

Vaccine

Volumn 30, Issue 2, 2012, Pages 225-230

  Huijbers, Elisabeth J M ^a   Femel, Julia ^a   Andersson, Karl ^b,c   Björkelund, Hanna ^b,c   Hellman, Lars ^a   Olsson, Anna Karin ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c Ridgeview Instruments AB   (Sweden)

Author keywords

Adjuvant; Angiogenesis; Cancer; Extra domain B; Immunization; Vaccine

Indexed keywords

CANCER VACCINE; FIBRONECTIN; FREUND ADJUVANT; IMMUNOGLOBULIN G; IMMUNOLOGICAL ADJUVANT; MONTANIDE ISA 720 CPG; RECOMBINANT PROTEIN; THIOREDOXIN; THIOREDOXIN FIBRONECTIN EXTRA DOMAIN B FUSION PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; FEMALE; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOLOGICAL TOLERANCE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, NEOPLASM; CANCER VACCINES; FEMALE; FIBRONECTINS; FREUND'S ADJUVANT; MANNITOL; MICE; MICE, INBRED C57BL; OLEIC ACIDS; PROTEIN STRUCTURE, TERTIARY;

EID: 84355161512     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.11.010     Document Type: Article

References (22)

1. Vernersson M., Ledin A., Johansson J., Hellman L. Generation of therapeutic antibody responses against IgE through vaccination. FASEB J 2002, 16:875-877.
2. Le Buanec H., Paturance S., Couillin I., Schnyder-Candrian S., Larcier P., Ryffel B., et al. Control of allergic reactions in mice by an active anti-murine IL-4 immunization. Vaccine 2007, 25:7206-7216.
3. Ma Y., HayGlass K.T., Becker A.B., Fan Y., Yang X., Basu S., et al. Novel recombinant interleukin-13 peptide-based vaccine reduces airway allergic inflammatory responses in mice. Am J Respir Crit Care Med 2007, 176:439-445.
4. Huijbers E.J., Ringvall M., Femel J., Kalamajski S., Lukinius A., Abrink M., et al. Vaccination against the extra domain-B of fibronectin as a novel tumor therapy. FASEB J 2010, 24:4535-4544.
5. Zardi L., Carnemolla B., Siri A., Petersen T.E., Paolella G., Sebastio G., et al. Transformed human cells produce a new fibronectin isoform by preferential alternative splicing of a previously unobserved exon. EMBO J 1987, 6:2337-2342.
6. Carnemolla B., Balza E., Siri A., Zardi L., Nicotra M.R., Bigotti A., et al. A tumor-associated fibronectin isoform generated by alternative splicing of messenger RNA precursors. J Cell Biol 1989, 108:1139-1148.
7. Castellani P., Viale G., Dorcaratto A., Nicolo G., Kaczmarek J., Querze G., et al. The fibronectin isoform containing the ED-B oncofetal domain: a marker of angiogenesis. Int J Cancer 1994, 59:612-618.
8. Astrof S., Hynes R.O. Fibronectins in vascular morphogenesis. Angiogenesis 2009, 12:165-175.
9. Ringvall M., Huijbers E.J., Ahooghalandari P., Alekseeva L., Andronova T., Olsson A.K., et al. Identification of potent biodegradable adjuvants that efficiently break self-tolerance-a key issue in the development of therapeutic vaccines. Vaccine 2009, 28:48-52.
10. Workman P., Balmain A., Hickman J.A., McNally N.J., Rohas A.M., Mitchison N.A., et al. UKCCCR guidelines for the welfare of animals in experimental neoplasia. Lab Anim 1988, 22:195-201.
11. Bally R.W., Gribnau T.C. Some aspects of the chromogen 3,3',5,5'-tetramethylbenzidine as hydrogen donor in a horseradish peroxidase assay. J Clin Chem Clin Biochem 1989, 10:791-796.
12. Hellman L. Therapeutic vaccines against IgE-mediated allergies. Expert Rev Vaccines 2008, 7:193-208.
13. Siegrist C.A., Pihlgren M., Tougne C., Efler S.M., Morris M.L., Al Adhami M.J., et al. Co-administration of CpG oligonucleotides enhances the late affinity maturation process of human anti-hepatitis B vaccine response. Vaccine 2004, 23:615-622.
14. Krieg A.M., Yi A.K., Matson S., Waldschmidt T.J., Bishop G.A., Teasdale R., et al. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 1995, 374:546-549.
15. Vollmer J., Krieg A.M. Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists. Adv Drug Deliv Rev 2009, 61:195-204.
16. Krieg A.M. Therapeutic potential of Toll-like receptor 9 activation. Nat Rev Drug Discov 2006, 5:471-484.
17. Gottenberg J.E., Chiocchia G. Dendritic cells and interferon-mediated autoimmunity. Biochimie 2007, 89:856-871.
18. Lawrence G.W., Saul A., Giddy A.J., Kemp R., Pye D. Phase I trial in humans of an oil-based adjuvant SEPPIC MONTANIDE ISA 720. Vaccine 1997, 15:176-178.
19. Saul A., Lawrence G., Smillie A., Rzepczyk C.M., Reed C., Taylor D., et al. Human phase I vaccine trials of 3 recombinant asexual stage malaria antigens with Montanide ISA 720 adjuvant. Vaccine 1999, 17:3145-3159.
20. Cooper C.L., Davis H.L., Morris M.L., Efler S.M., Adhami M.A., Krieg A.M., et al. CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B HBV vaccine in healthy adults: a double-blind phase I/II study. J Clin Immunol 2004, 24:693-701.
21. Cooper C.L., Davis H.L., Morris M.L., Efler S.M., Krieg A.M., Li Y., et al. Safety and immunogenicity of CPG 7909 injection as an adjuvant to Fluarix influenza vaccine. Vaccine 2004, 22:3136-3143.
22. Speiser D.E., Lienard D., Rufer N., Rubio-Godoy V., Rimoldi D., Lejeune F., et al. Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J Clin Invest 2005, 115:739-746.